Teva wins reversal of U.S. jury's $235 million GSK drug patent verdict

(Reuters) - A federal judge on Wednesday overturned a U.S. jury's verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg.

Source: Reuters: Health - March 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news